Background Treatment group imbalances in baseline stroke severity in the NINDS intravenous t-PA for acute stroke treatment trial led to controversy regarding the efficacy of tissue plasminogen activator (t-PA) in the treatment of acute ischemic stroke.
Purpose Describe the steps used to independently re-evaluate this trial.
Methods NIH appointed an independent multidisciplinary committee that gained access to the original data. We undertook analyses of t-PA efficacy accounting for this imbalance, as well as analyses to identify subgroups that experienced additional harm or benefit from t-PA. Analyses of time from stroke onset to treatment (OTT), blood pressure, and intracerebral hemorrhage are given as illustrations.
Results Despite subgroup imbalances in baseline stroke severity, when t-PA was administered to acute ischemic stroke patients according to study protocol, there was a statistically significant and clinically important benefit of t-PA treatment resulting in a higher likelihood of having a favorable clinical outcome at 3 months. Moreover, we were unable to identify subgroups of patients between which t-PA treatment effect differed, albeit these analyses had low power. These data failed to support the NINDS investigators' conclusion that effect of t-PA therapy diminished with increasing values of OTT within the protocol-specified 3 h time limit. In addition, the blood pressure measurements were highly variable and inconsistently determined so as to be too unreliable for inclusion in analysis.
Conclusion With new NIH requirements for data-sharing, the frequency of re-analysis of clinical trial data may increase substantially. This re-evaluation provides a blueprint for future re-evaluations of other trials. These best practices include re-analysis of the study data, after suitable replication, by an independent multidisciplinary committee, including a skilled statistical programmer analyst. Primary investigators should address significant errors determined in such re-analyses. Clinical Trials 2008; 5: 308—315. http://ctj.sagepub.com
Get full access to this article
View all access options for this article.
References
1.
The National Institute of Neurological Disorders and Stroke rt-PA.Tissue plasminogen activator for acute ischemic stroke. New England Journal of Medicine1995; 333(24): 1581-7.
2.
Reeves MJ, Arora S., Broderick JP et al. Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry. Stroke2005; 36(8): 1232-1340.
3.
Thom T.Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee . Circulation2006; 113(14): E696-E696.
4.
Wardlaw JM, Lindley RI, Lewis S.Thrombolysis for acute ischemic stroke: still a treatment for the few by the few. Western Journal of Medicine2002; 176(3): 198-9.
5.
Trotter G.Why were the benefits of tPA exaggerated? Western Journal of Medicine2002; 176(3): 194-7.
6.
Mann H.Alteplase for stroke - Uncertainty remains about efficacy. British Medical Journal2002; 324(7353): 1581.
7.
Mann J.Truths about the NINDS study: setting the record straight. Western Journal of Medicine2002; 176(3): 192-4.
8.
Ingall T., O'Fallon W., Asplund K. et al. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic strlke treatment trial. Stroke2004; 35: 2418-24.
9.
Brott T., Broderick J., Kothari R. et al. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke1997; 28(11): 2109-18.
10.
Kwatkowski TG, Libman RB, Frankel M. et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. New England Journal of Medicine1999; 340(23): 1781-7.
11.
Marler JR, Tilley BC, Lu M. et al. Early stroke treatment associated with better outcome - The NINDS rt-PA Stroke Study. Neurology2000; 55(11): 1649-55.
12.
Report of the t-PA review committee.National Institute for Neurologic Disorders and Stroke, 2004 . (Accessed at http://www.ninds.nih.gov/funding/review_committees/t-pa_review_committee/t-pa_committee_report.pdf).
13.
Clinical Review for PLA 96-0350. 1996. (Accessed at http://www.fda.gov/cder/biologics/review/altegen061896r2.pdf ).
14.
Brott T., Lu M., Kothari R. et al. Hypertension and its treatment in the NINDS rt-PA Stroke Trial . Stroke1998; 29(8): 1504-9.
15.
Wardlaw J., del Zoppo G., Yamaguchi T., Berge E.Thrombolysis for acute ischaemic stroke. Cochrane Database of Systematic Reviews2003(3).
16.
Clark W., Wissman S., Albers GW et al. Recombinant tissue-type Plasminogen Activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset: the ATLANTIS study: a randomized controlled trial. JAMA1999; 282(21): 2019-26.
17.
Clark WM, Albers GW, Madden KP et al. The rtPA (Alteplase) 0- to 6-hour acute stroke trial, Part A (A0276g): results of a double-blind, placebo-controlled, multicenter study . Stroke2000; 31: 811-6.
18.
Hacke W., Kaste M., Fieschi C. et al. Intravenous thrombolysis with recombinant tissue Plasminogen Activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA1995; 274: 1017-25.
19.
Hacke W., Kaste M., Fieschi C. et al. Randomized double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet1998; 352: 1245-51.
20.
The Atlantis E, Ecass and NINDS rt-PA Study Group Investigators.Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet2004 ; 363: 768-74.
21.
Hoffman JR, Cooper RJStroke thrombolysis: we need new data, not more reviews. Lancet Neurology2005; 4(4): 204-5.
22.
Mann J.NINDS Reanalysis Committee's reanalysis of the NINDS trial. Stroke2005; 36(2): 230.
23.
Smith B.NINDS Stroke Trial data reanalysis leaves issues unresolved. Stroke2005; 36(3): 529.
24.
Final NIHStatement on Sharing Research Data. 2003. (Accessed 8 April, 2005, at http://grants2.nih.gov/grants/guide/notice-files/NOT-OD-03-032.html).
